NCT00273546已完成3 期
A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) Versus Neoadjuvant Cisplatin Plus 5-Fluorouracil Followed by Concomitant Chemoradiotherapy to Improve the Overall Survival and Progression Free Survival in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 500
- 试验地点
- 7
- 主要终点
- Overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5-FU) or the control treatment (PF: Cisplatin plus 5-FU) followed by chemoradiotherapy.
研究概览
简要总结
- 1.To compare overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5FU) or the control treatment (PF: cisplatin plus 5-FU) followed by chemoradiotherapy in patients with locally advanced SCCHN.
- 2.The main secondary endpoint is progression free survival (PFS). The other secondary endpoints are to evaluate and compare improvement of local symptoms; time-to-treatment failure; quality of life; clinical complete response rate (CR and CR/PR); toxicity and to evaluate the relationship of tumor markers and response to therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Histologically or cytologically proven squamous cell carcinoma of the head/neck.
- •2.Primary tumor sites eligible: oral cavity, oropharynx, hypopharynx, larynx. Although they are admittedly of squamous cell types, the following tumors will be excluded because their responsiveness to chemotherapy may differ: nasal, paranasal cavities; nasopharynx.
- •3.Stage 3 or 4 disease without evidence of distant metastases verified with Chest X-Ray, abdominal ultrasound or CT (liver function test abnormalities); bone scan in case of local symptoms.
- •4.At least one uni or bidimensionally measurable lesion.
- •5.Tumor considered as inoperable after evaluation by a multidisciplinary team (surgeon, medical oncologist and radiation oncologist). Criteria include : Technical unresectablility-ie tumor fixation/invasion to base of the skull or cervical vertebrae involvement of the nasopharynx and fixed lymph nodes; Physician's decision based on low surgical curability which includes all T3-4 stages, all N2-3 stages excluding T1N2; organ preservation.
- •6.No previous chemotherapy or radiotherapy for any reason and no previous surgery for SCCHN (other than biopsy) are allowed at time of study entry.
- •7.Age ³ 18 years.
- •8.WHO performance status of 0-1
- •9.No active alcohol addiction
- •10.Life expectancy ³ 12 weeks
- •11.Signed informed consent prior to beginning protocol specific procedures
- •12.Adequate bone marrow, hepatic and renal functions as evidenced by the following: Hematology (Bone Marrow): Neutrophil count ³ 2.0 x 10 9/L; Platelet count ³ 100 X 10 9/L; Hemoglobin ³ 10g/dL; Hepatic function : Total bilirubin WNL; ASAT (SGOT) and ALAT (SGPT) £ 2.5 X ULN; Alkaline phosphatase £ 5 X ULN; patients with ASAT or ALAT > 1.5 x ULN associated with alkaline phosphatase > 2.5 x ULN are not eligible for the study; Renal function: the creatinine clearance ³ 60 ml/min (actual or calculated by the Cockcroft-Gault method as follows: Weight (kg) X (140-age)/K x serum creatinine.
- •13.Patients must be available for treatment and follow up. Patients registered on this trial must be treated and followed at the participating center.
排除标准
- •1.Pregnant or lactating women or women of childbearing potential not using adequate contraception.
- •2.Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years. Any prior treatment with radiotherapy or chemotherapy is an exclusion criterion.
- •3.Symptomatic peripheral neuropathy ³ grade 2 by NCIC-CTG criteria.
- •4.Symptomatic altered hearing > grade 2 by NCIC-CTG criteria.
- •5.Other serious illnesses or medical conditions including but no limited to: Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry; History of significant neurologic or psychiatric disorders including dementia or seizures; Active uncontrolled infection; Active peptic ulcer; Hypercalcemia; Chronic obstructive pulmonary disease requiring hospitalization during the year preceding study entry.
- •6.Patients requiring intravenous alimentation.
- •7.Patients who experienced a weight loss of more than 20% of their body weight in the 3 months preceding study entry.
- •8.Concurrent treatment with any other anticancer therapy
- •9.Participation in an investigational trial within 30 days of study entry.
结局指标
主要结局
Overall survival after treatment with the test tri-therapy (TPF: docetaxel plus cisplatin and 5-FU) or the control treatment (PF: Cisplatin plus 5-FU) followed by chemoradiotherapy.
次要结局
- The main secondary outcome is progression free survival (PFS).
- The other secondary endpoints are improvement of local symptoms;time-to-treatment failure;quality of life;
- clinical complete response rate (CR) and overall response rate(PR+CR) after chemotherapy and after locoregional therapy(chemoradiotherapy);
- duration of response(CR and CR+PR); toxicity.
研究者
研究点 (7)
Loading locations...
相似试验
已完成
3 期
Docetaxel in Breast CancerBreast CancerNCT00312208Sanofi3,299
已完成
3 期
Docetaxel in Node Positive Adjuvant Breast CancerBreast CancerNCT00688740Sanofi1,491
已完成
3 期
Survival Study of Docetaxel and Carboplatin as Neo-Adjuvant Vs Adjuvant Chemotherapy in Early Stage NSLCNon-small Cell Lung CancerNCT00321334Chinese Society of Lung Cancer410
已完成
3 期
Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and NeckHead and Neck Squamous Cell CarcinomaNCT01086826Associazione Volontari Pazienti Oncologici320
已完成
3 期
BIG 02/98 Docetaxel - Breast CancerBreast NeoplasmsNCT00174655Sanofi2,887